Source: ERS Course 2019 - Summer school of adult respiratory medicine



Rating:

Share or cite this content

Citations should be made in the following way:
Rudolf M. Huber (Germany). SCLC management. ERS Course 2019 - Summer school of adult respiratory medicine

Member's Comments

No comment yet.

Related content which might interest you: NSCLC management Source: ERS Course 2018 - Summer school of adult respiratory medicine Year: 2018 NSCLC management Source: ERS Skills Course 2017 - Summer school of adult respiratory medicine Year: 2017 NSCLC management Source: ERS Course 2019 - Summer school of adult respiratory medicine Year: 2019 NSCLC management Source: ERS Skills Course 2016 Year: 2016 Therapeutic management of ALK+ nonsmall cell lung cancer patients Source: Eur Respir J 2015; 46: 230-242 Year: 2015 SCLC – Management Source: ERS Skills Course 2016 Year: 2016 The method of individualisation of treatment and prognosis for advanced non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Challenges in the management of SCLC Source: ERS webinar 2021: Challenges in the management of SCLC Year: 2021 Challenges in the management of SCLC Part 2: Extensive disease, prophylaxis/treatment of brain metastases Source: ERS webinar 2021: Challenges in the management of SCLC Part 2: Extensive disease, prophylaxis/treatment of brain metastases Year: 2021 Interdisciplinary multimodality management of stage III nonsmall cell lung cancer Source: Eur Respir Rev, 28 (152) 190024; 10.1183/16000617.0024-2019 Year: 2019 Results of surgical treatment in elderly patients with non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 463s Year: 2002 The role of palliative radiotherapy in locally advanced non small cell lung cancer Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007 Characterization and management of elderly and very elderly patients with non-small cell lung cancer Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 Our experience with crizotinib in the treatment of non-small cell lung cancer Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 Utilisation of biomarker testing to guide therapy in non-small cell lung cancer in a regional lung cancer service Source: International Congress 2018 – Genetics in chronic pulmonary diseases Year: 2018 Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients Source: ERJ Open Res, 4 (1) 00058-2017; 10.1183/23120541.00058-2017 Year: 2018 Current challenges in the management of nonsmall cell lung cancer brain metastases Source: Eur Respir J, 55 (1) 1901686; 10.1183/13993003.01686-2019 Year: 2020 Towards personalized treatment in non-small-cell lung carcinoma Source: Virtual Congress 2020 – Management issues in thoracic oncology Year: 2020